Imdelltra

News

Amgen's Imdelltra scores again in small cell lung cancer

Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.

News

Amgen, AZ will pilot FDA's real-time clinical trial plan

The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.

News

Amgen's BiTE for lung cancer backed for EU approval

Amgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

News

Amgen adds BiTE to its cancer range as FDA clears Imdelltra

Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie

Amgen's Imdelltra scores again in small cell lung cancer

Amgen, AZ will pilot FDA's real-time clinical trial plan

Amgen's BiTE for lung cancer backed for EU approval

11 blockbuster drugs to look out for in 2025

Amgen adds BiTE to its cancer range as FDA clears Imdelltra

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Imdelltra

Editor's Picks